GEP20207095B - Fused bicyclic heteroaryl derivatives having activity as phd inhibitors - Google Patents
Fused bicyclic heteroaryl derivatives having activity as phd inhibitorsInfo
- Publication number
- GEP20207095B GEP20207095B GEAP201614608A GEAP2016014608A GEP20207095B GE P20207095 B GEP20207095 B GE P20207095B GE AP201614608 A GEAP201614608 A GE AP201614608A GE AP2016014608 A GEAP2016014608 A GE AP2016014608A GE P20207095 B GEP20207095 B GE P20207095B
- Authority
- GE
- Georgia
- Prior art keywords
- activity
- bicyclic heteroaryl
- fused bicyclic
- heteroaryl derivatives
- phd inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 2
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 2
- 208000033626 Renal failure acute Diseases 0.000 abstract 2
- 201000011040 acute kidney failure Diseases 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000023516 stroke disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504565.1A GB201504565D0 (en) | 2015-03-18 | 2015-03-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20207095B true GEP20207095B (en) | 2020-04-10 |
Family
ID=53051992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201614608A GEP20207095B (en) | 2015-03-18 | 2016-03-17 | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10287286B2 (OSRAM) |
| EP (1) | EP3271357B1 (OSRAM) |
| JP (1) | JP6726681B2 (OSRAM) |
| KR (1) | KR102609431B1 (OSRAM) |
| CN (1) | CN107531698B (OSRAM) |
| AU (1) | AU2016234209B2 (OSRAM) |
| BR (1) | BR112017019653B1 (OSRAM) |
| CA (1) | CA2979024C (OSRAM) |
| CL (1) | CL2017002354A1 (OSRAM) |
| CO (1) | CO2017009353A2 (OSRAM) |
| CR (1) | CR20170468A (OSRAM) |
| DK (1) | DK3271357T3 (OSRAM) |
| DO (1) | DOP2017000209A (OSRAM) |
| EA (1) | EA035739B1 (OSRAM) |
| EC (1) | ECSP17069696A (OSRAM) |
| ES (1) | ES2774052T3 (OSRAM) |
| GB (1) | GB201504565D0 (OSRAM) |
| GE (1) | GEP20207095B (OSRAM) |
| HU (1) | HUE047918T2 (OSRAM) |
| IL (1) | IL254277B (OSRAM) |
| MX (1) | MX2017011902A (OSRAM) |
| MY (1) | MY194873A (OSRAM) |
| NZ (1) | NZ735631A (OSRAM) |
| PE (1) | PE20180656A1 (OSRAM) |
| PH (1) | PH12017501699B1 (OSRAM) |
| PT (1) | PT3271357T (OSRAM) |
| SG (1) | SG11201707280VA (OSRAM) |
| TN (1) | TN2017000384A1 (OSRAM) |
| UA (1) | UA123668C2 (OSRAM) |
| WO (1) | WO2016148306A1 (OSRAM) |
| ZA (1) | ZA201706612B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017222417B2 (en) | 2016-02-24 | 2020-07-09 | Pfizer Inc. | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors |
| EP3668858A1 (en) | 2017-08-14 | 2020-06-24 | Pfizer Inc | Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives |
| KR102830577B1 (ko) * | 2018-09-13 | 2025-07-08 | 깃세이 야쿠힌 고교 가부시키가이샤 | 이미다조피리디논 화합물 |
| CN110950806A (zh) * | 2019-11-14 | 2020-04-03 | 安庆博曼生物技术有限公司 | 四乙基氯化铵催化嘧啶环羟基氯代制备方法 |
| JP7504822B2 (ja) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | イミダゾピリジノン化合物を含む医薬組成物 |
| US11718622B2 (en) | 2020-03-16 | 2023-08-08 | Exelixis Inc. | Heterocyclic adenosine receptor antagonists |
| CN115413277B (zh) * | 2020-04-20 | 2023-08-01 | 深圳市塔吉瑞生物医药有限公司 | 吡嗪取代的烟酰胺的固体形式及其制备和用途 |
| AR123848A1 (es) * | 2020-10-20 | 2023-01-18 | Amgen Inc | Compuestos espiro heterocíclicos y métodos de uso |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| IL312220A (en) | 2021-10-28 | 2024-06-01 | Insilico Medicine Ip Ltd | Prolyl hydroxylase domain-containing protein (phd) inhibitors and uses thereof |
| JP2025500892A (ja) * | 2021-12-17 | 2025-01-15 | アケビア セラピューティクス インコーポレイテッド | 選択的ｐｈｄ１阻害剤化合物、組成物、及び使用方法 |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4209621A (en) | 1979-04-27 | 1980-06-24 | American Cyanamid Company | (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines |
| DK135184A (da) | 1983-03-03 | 1984-10-10 | Riker Laboratories Inc | Triazol(4,3-c)- og triazol(1,5-c)pyrimidiner |
| US4572910A (en) * | 1983-03-03 | 1986-02-25 | Riker Laboratories, Inc. | Triazolo[1,5-c]pyrimidines substituted by nitrogen-containing heterocyclic rings |
| SK18412002A3 (sk) | 2000-06-30 | 2003-06-03 | Wyeth | Použitie substituovaných triazolopyrimidínových derivátov a farmaceutický prostriedok s ich obsahom |
| JP2010065026A (ja) | 2008-08-13 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | ピリジル−トリアゾロピリミジン誘導体又はその塩、並びにそれらを含有する有害生物防除剤 |
| JP2010065024A (ja) | 2008-08-14 | 2010-03-25 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリミジン誘導体又はその塩を含有する有害生物防除剤 |
| TWI485150B (zh) * | 2009-07-17 | 2015-05-21 | Japan Tobacco Inc | 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用 |
| JP2011168582A (ja) | 2010-01-21 | 2011-09-01 | Ishihara Sangyo Kaisha Ltd | トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤 |
| JPWO2014030716A1 (ja) * | 2012-08-23 | 2016-08-08 | 田辺三菱製薬株式会社 | ピラゾロピリミジン化合物 |
-
2015
- 2015-03-18 GB GBGB1504565.1A patent/GB201504565D0/en not_active Ceased
-
2016
- 2016-03-17 EA EA201792057A patent/EA035739B1/ru unknown
- 2016-03-17 EP EP16715122.4A patent/EP3271357B1/en active Active
- 2016-03-17 PT PT167151224T patent/PT3271357T/pt unknown
- 2016-03-17 CN CN201680022416.0A patent/CN107531698B/zh active Active
- 2016-03-17 CR CR20170468A patent/CR20170468A/es unknown
- 2016-03-17 CA CA2979024A patent/CA2979024C/en active Active
- 2016-03-17 US US15/558,824 patent/US10287286B2/en active Active
- 2016-03-17 MX MX2017011902A patent/MX2017011902A/es active IP Right Grant
- 2016-03-17 MY MYPI2017703420A patent/MY194873A/en unknown
- 2016-03-17 KR KR1020177030091A patent/KR102609431B1/ko active Active
- 2016-03-17 PE PE2018000126A patent/PE20180656A1/es unknown
- 2016-03-17 UA UAA201708877A patent/UA123668C2/uk unknown
- 2016-03-17 WO PCT/JP2016/059782 patent/WO2016148306A1/en not_active Ceased
- 2016-03-17 BR BR112017019653-0A patent/BR112017019653B1/pt active IP Right Grant
- 2016-03-17 NZ NZ735631A patent/NZ735631A/en unknown
- 2016-03-17 HU HUE16715122A patent/HUE047918T2/hu unknown
- 2016-03-17 JP JP2017549107A patent/JP6726681B2/ja active Active
- 2016-03-17 DK DK16715122.4T patent/DK3271357T3/da active
- 2016-03-17 PH PH1/2017/501699A patent/PH12017501699B1/en unknown
- 2016-03-17 GE GEAP201614608A patent/GEP20207095B/en unknown
- 2016-03-17 SG SG11201707280VA patent/SG11201707280VA/en unknown
- 2016-03-17 TN TNP/2017/000384A patent/TN2017000384A1/en unknown
- 2016-03-17 AU AU2016234209A patent/AU2016234209B2/en active Active
- 2016-03-17 ES ES16715122T patent/ES2774052T3/es active Active
-
2017
- 2017-09-03 IL IL254277A patent/IL254277B/en active IP Right Grant
- 2017-09-14 CO CONC2017/0009353A patent/CO2017009353A2/es unknown
- 2017-09-15 CL CL2017002354A patent/CL2017002354A1/es unknown
- 2017-09-18 DO DO2017000209A patent/DOP2017000209A/es unknown
- 2017-10-02 ZA ZA2017/06612A patent/ZA201706612B/en unknown
- 2017-10-18 EC ECIEPI201769696A patent/ECSP17069696A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20207095B (en) | Fused bicyclic heteroaryl derivatives having activity as phd inhibitors | |
| PH12020500485A1 (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
| CY1123391T1 (el) | (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι | |
| CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| EA201890200A1 (ru) | Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201891917A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| EA201790660A1 (ru) | Ингибитор киназ | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| EA201891049A1 (ru) | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 | |
| UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| GEP20186938B (en) | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | |
| EA201791289A1 (ru) | Ингибиторы клеточного некроза и связанные с ними способы | |
| MY181641A (en) | Amino pyran ring derivative and composition and use thereof | |
| PH12017500977A1 (en) | 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase | |
| EA201692300A1 (ru) | Производные карбоксамида | |
| EA201891239A1 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| MX379373B (es) | Derivado de sulfonamida heterocíclico y medicina que contiene el mismo. | |
| EA202190398A1 (ru) | Конденсированное кольцевое производное, применяемое в качестве ингибитора fgfr4 | |
| EA201892382A1 (ru) | Замещенные бициклические гетероциклические соединения | |
| MX2017009853A (es) | Prevencion o tratamiento de enfermedades urinarias o gotosas. | |
| PH12016502223A1 (en) | Pyrazine derivatives | |
| WO2015181837A3 (en) | Novel compounds as anti-tubercular agents |